Ligand Pharmaceuticals
LGND
LGND
195 hedge funds and large institutions have $946M invested in Ligand Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 66 increasing their positions, 77 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
195
Holders Change
-8
Holders Change %
-3.94%
% of All Funds
3.11%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
66
Reduced
77
Closed
27
Calls
$5.38M
Puts
$2.39M
Net Calls
+$3M
Net Calls Change
+$1.63M
Top Buyers
1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$9.27M |
2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.97M |
3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$4.07M |
4 |
D.E. Shaw & Co
New York
|
+$3.26M |
5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.45M |
Top Sellers
1 |
Man Group
London,
United Kingdom
|
-$10.5M |
2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$4.11M |
3 |
BlackRock
New York
|
-$3.9M |
4 |
CC
Chicago Capital
Chicago,
Illinois
|
-$3.82M |
5 |
BC
Burney Company
Reston,
Virginia
|
-$3.75M |